1. Show article details.

    Immunomedics to Participate in Upcoming Healthcare Conferences

    GlobeNewswire – 8:00 AM ET 05/28/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences: Live audio webcast of the fireside chats will be accessible and available for replay from the Company’s website at https://immunomedics.com...

  2. Show article details.

    BRIEF-Immunomedics Says Harout Semerjian Decided To Step Down From Role As President And CEO

    Reuters – 5:05 PM ET 05/27/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS ANNOUNCES LEADERSHIP CHANGE AND PROVIDES BUSINESS UPDATE AMID COVID-19. * Immunomedics Inc (IMMU) - HAROUT SEMERJIAN HAS DECIDED TO STEP DOWN FROM HIS ROLE AS PRESIDENT AND CEO OF IMMUNOMEDICS. * Immunomedics Inc (IMMU) - IS NOT EXPECTING TO INITIATE A CEO SEARCH UNTIL GLOBAL COVID-19 SITUATION IS STABILIZED.

  3. Show article details.

    Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

    GlobeNewswire – 4:00 PM ET 05/27/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update on a leadership change as well as the Company’s efforts to navigate through the ongoing coronavirus pandemic.

  4. Show article details.

    BRIEF-Immunomedics To Present New Trodelvy Data In Non-Breast Cancer Indications At 2020 ASCO Virtual Meeting

    Reuters – 5:58 PM ET 05/13/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS TO PRESENT NEW TRODELVY™ DATA IN NON-BREAST CANCER INDICATIONS AT THE 2020 ASCO VIRTUAL MEETING Source text for Eikon: Further company coverage:

  5. Show article details.

    Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting

    GlobeNewswire – 5:01 PM ET 05/13/2020

    Immunomedics, Inc. (IMMU), , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its recently FDA-approved ADC, Trodelvy, showed clinical activity in cisplatin-ineligible patients with metastatic urothelial cancer and in patients with previously-treated metastatic endometrial cancer.

  6. Show article details.

    Immunomedics to Participate in BofA Securities 2020 Health Care Conference

    GlobeNewswire – 8:00 AM ET 05/07/2020

    Immunomedics, Inc. (IMMU), , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 2:20 p.m. Eastern Time.

  7. Show article details.

    BRIEF-Immunomedics Reports Q1 Loss Per Share Of $0.44

    Reuters – 6:29 PM ET 05/06/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE. * Q1 LOSS PER SHARE $0.44. * Q1 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA. * ASCENT STUDY STOPPED EARLY DUE TO COMPELLING EVIDENCE OF EFFICACY ACROSS MULTIPLE ENDPOINTS, TOPLINE RESULTS AROUND MID-2020.

  8. Show article details.

    Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

    GlobeNewswire – 4:00 PM ET 05/06/2020

    Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study stopped early due to compelling evidence of efficacy across multiple endpoints, topline results around mid-2020 MORRIS PLAINS, N.J., May 06, 2020 -- Immunomedics, Inc. (IMMU), , a leading biopharmaceutical com...

  9. Show article details.

    BRIEF-Immunomedics Announces Commercial Availability Of Trodelvy™ In United States

    Reuters – 9:01 AM ET 05/04/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS ANNOUNCES COMMERCIAL AVAILABILITY OF TRODELVY™ IN UNITED STATES Source text for Eikon: Further company coverage:

  10. Show article details.

    Immunomedics Announces Commercial Availability of TRODELVY™ in the United States

    GlobeNewswire – 8:00 AM ET 05/04/2020

    Immunomedics, Inc. (IMMU), , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy is now available through major specialty distributors in the United States and that the first patient was treated with commercial product on April 29, 2020.

  11. Show article details.

    Immunomedics Announces Closing Of Public Offering Of Common Stock

    GlobeNewswire – 4:05 PM ET 05/01/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the closing of its previously announced underwritten public offering of common stock.

  12. Show article details.

    Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020

    GlobeNewswire – 8:00 AM ET 04/30/2020

    Immunomedics, Inc. (IMMU), , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, May 6, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the first quarter of 2020 and provide a corporate update. To access the conference call, please dial 303-2523 or 237-1755 using the Conference ID 9146008.

  13. Show article details.

    BRIEF-Immunomedics Announces Pricing Of Public Offering Of Common Stock

    Reuters – 11:52 PM ET 04/28/2020

    Immunomedics Inc (IMMU): * ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 14,736,860 SHARES OF ITS COMMON STOCK AT A PRICE OF $28.50 PER SHARE Source text for Eikon: Further company coverage:

  14. Show article details.

    Immunomedics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 11:50 PM ET 04/28/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the pricing of an underwritten public offering of 14,736,860 shares of its common stock at a public offering price of $28.50 per share, representing gross proceeds of approximately $420 million.

  15. Show article details.

    BRIEF-Immunomedics Announces Proposed Public Offering Of Common Stock

    Reuters – 4:04 PM ET 04/27/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. * Immunomedics Inc (IMMU) - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $350 MILLION OF SHARES OF ITS COMMON STOCK. * Immunomedics Inc (IMMU) - INTENDS TO USE NET PROCEEDS FROM OFFERING PRIMARILY TO SUPPORT COMMERCIAL LAUNCH OF TRODELVY™ IN U.S. Source text for Eikon: Further company coverage:

  16. Show article details.

    Immunomedics Announces Proposed Public Offering Of Common Stock

    GlobeNewswire – 4:01 PM ET 04/27/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced it has commenced an underwritten public offering of $350,000,000 of shares of its common stock.

  17. Show article details.

    CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer

    GlobeNewswire – 9:15 PM ET 04/24/2020

    In a release issued under the same headline on Friday, April 24th by Everest Medicines , at the end of the subheading, please note that it should read as “breast cancer”, not “break cancer”. The corrected release follows: Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for p...

  18. Show article details.

    Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer

    GlobeNewswire – 7:00 AM ET 04/24/2020

    Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the U.S. Food and Drug Administration has approved the Biologics License Application submitted by Immunomedics, Inc. (IMMU) for sacituzumab govitecan-hziy for...

  19. Show article details.

    Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

    GlobeNewswire – 8:00 AM ET 04/23/2020

    First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory metastatic triple-negative breast cancer Company to Host Conference Call at 5:00 p.m. Eastern Time MORRIS PLAINS, N.J., April 23, 2020 --  Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the...

  20. Show article details.

    Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug

    MarketWatch – 2:20 PM ET 04/22/2020

    Shares of Immunomedics Inc. (IMMU) gained 1% in trading on Wednesday after the Food and Drug Adminstration approved Trodelvy, the company's breast-cancer treatment. The drug is approved to treat patients with metastatic triple- negative breast cancer who have received at least two prior therapies. The regulator on Friday approved a new breast- cancer treatment developed by Seattle Genetics Inc..

Page:

Today's and Upcoming Events

  • Aug
    05

    IMMU to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    06

    IMMU announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.